CRSP
Crispr Therapeutics Ag Earnings
$46.25
Earnings Summary
Revenue | $0.86Mn |
Net Profits | $-130.61Mn |
Net Profit Margins | -15117.25% |
Crispr Therapeutics Ag’s revenue fell -97.53% since last year same period to $0.86Mn in the Q4 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -2.81% fall in its revenue since last 3-months.
Crispr Therapeutics Ag’s net profit fell -250.07% since last year same period to $-130.61Mn in the Q4 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -22.71% fall in its net profits since last 3-months.
Crispr Therapeutics Ag’s net profit margin fell -14080.9% since last year same period to -15117.25% in the Q4 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -26.26% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.1 |
EPS Estimate Current Year | -1.1 |
Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.1 - a 5.98% jump from last quarter’s estimates.
Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.1.
Key Ratios
Earning Per Share (EPS) | 0 |
Crispr Therapeutics Ag’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Crispr Therapeutics Ag has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-11 | -1.1 | 0 | 100% |
